Medarex/Bristol's Ipilimumab Shows Off Long-Term Survival Data At ASCO
This article was originally published in Pharmaceutical Approvals Monthly
Two-year melanoma survival data from three Phase II studies of Medarex/Bristol-Myers Squibbs' immunotherapeutic ipilimumab presented at the American Society of Clinical Oncology meeting May 31 bode well for an ongoing pivotal Phase III study and an eventual first approval for the oncologic
You may also be interested in...
Melanoma drug’s side effects indicate immune-boosting cancer drug’s effectiveness, investigator tells “The Pink Sheet” DAILY.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.